Todos Medical Ltd. (TOMDF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Todos Medical Ltd. (TOMDF) trades at $0.00. Todos Medical Ltd. is a vitro diagnostics company focused on developing and commercializing blood tests for cancer and Alzheimer's disease detection. Market cap: $1,408, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for TOMDF: TOMDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TOMDF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TOMDF: 1/1 perspectives are bearish.
How is this calculated? →Todos Medical Ltd. (TOMDF) Healthcare & Pipeline Overview
Todos Medical Ltd. is a diagnostics company specializing in cancer and Alzheimer's disease detection through blood tests, including proprietary technologies like Total Biochemical Infrared Analysis, operating within the competitive healthcare diagnostics market and offering immune support supplements like Tollovid.
What Is the Investment Thesis for TOMDF?
Todos Medical Ltd. presents a speculative investment opportunity within the diagnostics sector. The company's focus on early cancer and Alzheimer's detection through proprietary blood tests like TBIA and LPT could drive future revenue growth if clinical trials and commercialization efforts are successful. The ongoing Phase 2 clinical trial for Tollovir, an antiviral treatment for COVID-19, represents a potential catalyst. However, the company's negative profit margin of -324.8% and OTC market listing indicate substantial financial risks. Investors should carefully consider the high beta of 9.92, reflecting significant stock price volatility, and the competitive landscape before investing. Success hinges on navigating regulatory hurdles, securing partnerships, and demonstrating clinical efficacy.
Based on FMP financials and quantitative analysis
TOMDF Key Highlights
- Gross Margin of 56.0% indicates potential profitability in its diagnostic tests and supplements.
- Negative Profit Margin of -324.8% reflects ongoing losses and the need for improved cost management.
- The company has 7 employees, indicating a small operational scale and potential for scalability.
- Tollovir is in Phase 2 clinical trials, representing a potential value driver if approved.
- The company operates in the healthcare sector, which is experiencing increased demand for diagnostic solutions.
Who Are TOMDF's Competitors?
TOMDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| ICLR ICON Public Limited Company | $170.94 | -1.23% | $13.09B | 50 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TOMDF's Key Strengths?
- Proprietary cancer-screening technology (TBIA).
- Focus on early detection of cancer and Alzheimer's disease.
- Development of Tollovir, an antiviral treatment for COVID-19.
- Existing collaboration agreements with healthcare providers.
What Are TOMDF's Weaknesses?
- Negative profit margin (-324.8%).
- Limited number of employees (7).
- OTC market listing indicates higher risk.
- Dependence on successful clinical trials and regulatory approvals.
What Could Drive TOMDF Stock Higher?
- Results from Phase 2 clinical trials for Tollovir expected in Q4 2026.
- Expansion of strategic partnerships and distribution agreements with healthcare providers.
- Development and commercialization of new cancer diagnostic tests.
- Geographic expansion into international markets.
What Are the Key Risks for TOMDF?
- Financial-distress signal — its Altman Z-Score of -12.90 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials for Tollovir.
- Regulatory hurdles and delays in approvals for diagnostic tests.
- Competition from established diagnostic companies.
- Limited financial resources and negative profit margin.
- OTC market listing indicates higher risk and volatility.
What Are the Growth Opportunities for TOMDF?
- Expansion of Cancer Diagnostic Product Line: Todos Medical can expand its cancer diagnostic product line beyond breast and colon cancer to include tests for other prevalent cancers. The global cancer diagnostics market is projected to reach $26.7 billion by 2027, offering a substantial opportunity for growth. Successful development and commercialization of new cancer diagnostic tests could significantly increase revenue streams within the next 3-5 years.
- Commercialization of Tollovir: Successful completion of Phase 2 clinical trials and subsequent regulatory approval for Tollovir as a COVID-19 antiviral treatment would represent a significant growth opportunity. The market for COVID-19 treatments remains substantial, and Tollovir could capture a share of this market if proven effective. Commercialization could begin within the next 1-2 years, pending clinical trial results and regulatory approvals.
- Strategic Partnerships and Distribution Agreements: Todos Medical can pursue strategic partnerships and distribution agreements with healthcare providers, hospitals, and diagnostic laboratories to expand its market reach. Collaborations with established players in the healthcare industry can accelerate the adoption of its diagnostic tests and supplements. These partnerships can be established within the next year, leading to increased sales and market penetration.
- Geographic Expansion: Todos Medical can expand its geographic presence beyond the United States and Israel to target other international markets with high unmet needs for cancer and Alzheimer's disease diagnostics. Entering new markets requires regulatory approvals and establishing distribution networks, but it offers a significant opportunity for long-term growth. Expansion into European and Asian markets could begin within the next 3-5 years.
- Development of Alzheimer's Disease Diagnostics: Todos Medical can focus on developing and commercializing blood tests for the early detection of Alzheimer's disease. The market for Alzheimer's diagnostics is growing rapidly, driven by an aging population and the need for early intervention. Successful development of accurate and reliable Alzheimer's diagnostic tests could generate substantial revenue within the next 3-5 years.
What Opportunities Does TOMDF Have?
- Expansion of cancer diagnostic product line.
- Commercialization of Tollovir.
- Strategic partnerships and distribution agreements.
- Geographic expansion into international markets.
What Threats Does TOMDF Face?
- Competition from established diagnostic companies.
- Regulatory hurdles and delays in approvals.
- Failure of clinical trials for Tollovir.
- Limited financial resources.
What Are TOMDF's Competitive Advantages?
- Proprietary Technology: Total Biochemical Infrared Analysis (TBIA) is a proprietary cancer-screening technology.
- Focus on Early Detection: Emphasis on early detection of cancer and Alzheimer's disease addresses a critical need.
- Tollovid: A 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses provides a revenue stream.
- Tollovir: An antiviral treatment for COVID-19 that is in Phase 2 clinical trial.
What Does TOMDF Do?
Todos Medical Ltd., incorporated in 2010 and headquartered in Tel Aviv, Israel, is a vitro diagnostics company dedicated to the development and commercialization of blood tests for the early detection of cancer and Alzheimer's disease. The company's core technology revolves around Total Biochemical Infrared Analysis (TBIA), a proprietary cancer-screening platform that analyzes the influence of cancer on the immune system through peripheral blood spectroscopy. Todos Medical also offers the Lymphocyte Proliferation Test (LPT), a diagnostic blood test assessing the ability of lymphocytes and monocytes to withstand mitogenic stimulation. Their product line includes TM-B1 and TM-B2 tests for breast cancer screening, and the TMC blood test for colon cancer diagnosis. In addition to cancer diagnostics, Todos Medical provides Tollovid, a 3CL protease inhibitor dietary supplement designed to support healthy immune function against circulating coronaviruses. Tollovir, an antiviral treatment for COVID-19, is currently in Phase 2 clinical trials. Todos Medical collaborates with Integrated Health LLC and other companies to develop SARS-nCoV-2 screening tests and distribute COVID-19 test kits. The company aims to improve early disease detection and patient outcomes through innovative diagnostic solutions.
What Products and Services Does TOMDF Offer?
- Develop blood tests for cancer detection.
- Develop blood tests for Alzheimer's disease detection.
- Offer Total Biochemical Infrared Analysis (TBIA) for cancer screening.
- Provide Lymphocyte Proliferation Test (LPT) for immune system assessment.
- Offer TM-B1 and TM-B2 tests for breast cancer screening.
- Provide TMC blood test for colon cancer diagnosis.
- Offer Tollovid, a dietary supplement for immune support against coronaviruses.
- Develop Tollovir, an antiviral treatment for COVID-19 (in Phase 2 clinical trial).
How Does TOMDF Make Money?
- Develop and commercialize diagnostic blood tests for cancer and Alzheimer's disease.
- Generate revenue through the sale of diagnostic tests to healthcare providers and laboratories.
- Offer Tollovid, a dietary supplement, directly to consumers and through retail channels.
- Potentially generate revenue through the sale of Tollovir, an antiviral treatment for COVID-19, if approved.
What Industry Does TOMDF Operate In?
Todos Medical Ltd. operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and evolving regulatory landscapes. The market for cancer and Alzheimer's disease diagnostics is substantial and growing, driven by an aging population and increasing awareness of early detection benefits. Competition includes established players like ACUS and emerging biotech firms focused on novel diagnostic technologies. Todos Medical's success depends on its ability to differentiate its proprietary TBIA technology and secure regulatory approvals in a timely manner. The company also faces competition from companies developing COVID-19 treatments and immune support supplements.
Who Are TOMDF's Key Customers?
- Healthcare providers (doctors, clinics, hospitals).
- Diagnostic laboratories.
- Patients seeking early detection of cancer and Alzheimer's disease.
- Consumers seeking immune support supplements.
Company Profile
Todos Medical Ltd. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Tel Aviv, IL. The company is led by CEO Gerald E. Commissiong. TOMDF has traded publicly since 2017.
How Todos Medical Ltd. Is Valued
Todos Medical Ltd. carries a market capitalization of 1K, placing it in the micro-cap category.
ROE 84%Key Financial Metrics
Return on equity for Todos Medical Ltd. stands at 83.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.20 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Todos Medical Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.90 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 12 insider filings for Todos Medical Ltd. break down as 9 sales and 3 purchases. On net that is roughly 3.4M shares acquired (about $192K) — insiders putting money in tends to read as conviction.
TOMDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary cancer-screening technology (TBIA).
- Focus on early detection of cancer and Alzheimer's disease.
- Development of Tollovir, an antiviral treatment for COVID-19.
- Existing collaboration agreements with healthcare providers.
Bear Case
- Negative profit margin (-324.8%).
- Limited number of employees (7).
- OTC market listing indicates higher risk.
- Dependence on successful clinical trials and regulatory approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
TOMDF Latest News
No recent news available for TOMDF.
TOMDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TOMDF.
Price Targets
Wall Street price target analysis for TOMDF.
TOMDF MoonshotScore
What does this score mean?
The MoonshotScore rates TOMDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gerald E. Commissiong
CEO
Gerald E. Commissiong serves as the CEO of Todos Medical Ltd. His background includes experience in the healthcare and biotechnology sectors, with a focus on diagnostics and therapeutics. He has held leadership positions in various companies, contributing to strategic planning, business development, and product commercialization. His expertise encompasses regulatory affairs, clinical trial management, and market access strategies. He is responsible for managing the company's operations and driving its growth initiatives.
Track Record: Under Gerald E. Commissiong's leadership, Todos Medical Ltd. has focused on developing and commercializing blood tests for cancer and Alzheimer's disease detection. He has overseen the advancement of the company's proprietary TBIA technology and the clinical development of Tollovir. His strategic decisions have aimed to expand the company's product line, secure partnerships, and navigate the regulatory landscape. However, the company's financial performance remains a challenge.
TOMDF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Todos Medical Ltd. may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower liquidity and wider bid-ask spreads.
- Higher potential for fraud and manipulation.
- Greater price volatility and risk of delisting.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any history of stock promotion or pump-and-dump schemes.
- Development of proprietary cancer-screening technology (TBIA).
- Ongoing Phase 2 clinical trial for Tollovir.
- Collaboration agreements with healthcare providers.
- Focus on addressing unmet needs in cancer and Alzheimer's disease diagnostics.
TOMDF Healthcare Stock FAQ
What does Todos Medical Ltd. do?
Todos Medical Ltd. is a vitro diagnostics company that develops and commercializes blood tests for the early detection of cancer and Alzheimer's disease. The company's core technology revolves around Total Biochemical Infrared Analysis (TBIA), a proprietary cancer-screening platform. They also offer the Lymphocyte Proliferation Test (LPT) for immune system assessment. In addition to diagnostics, Todos Medical provides Tollovid, a dietary supplement for immune support, and is developing Tollovir, an antiviral treatment for COVID-19 currently in Phase 2 clinical trials. The company aims to improve patient outcomes through innovative diagnostic solutions.
What do analysts say about TOMDF stock?
As of March 17, 2026, there is limited analyst coverage available for Todos Medical Ltd. (TOMDF) due to its OTC market listing and small market capitalization. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's negative profitability. Growth considerations revolve around the successful completion of clinical trials for Tollovir and the commercialization of its diagnostic tests. Investors should conduct thorough due diligence and consider the inherent risks associated with investing in micro-cap OTC stocks before making any investment decisions.
What are the main risks for TOMDF?
The main risks for Todos Medical Ltd. include the potential failure of clinical trials for Tollovir, which could significantly impact its future revenue prospects. Regulatory hurdles and delays in approvals for its diagnostic tests also pose a risk. The company faces strong competition from established diagnostic companies with greater resources and market presence. Its limited financial resources and negative profit margin create financial instability. Additionally, the OTC market listing indicates higher risk and volatility compared to stocks listed on major exchanges.
What are the key factors to evaluate for TOMDF?
Evaluate TOMDF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does TOMDF data refresh on this page?
TOMDF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TOMDF's recent stock price performance?
Todos Medical Ltd. (TOMDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary cancer-screening technology (TBIA). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TOMDF overvalued or undervalued right now?
Valuing Todos Medical Ltd. (TOMDF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TOMDF?
Before investing in Todos Medical Ltd. (TOMDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 17, 2026.
- Financial data may be limited due to the company's OTC market listing.
- Clinical trial outcomes are subject to uncertainty.